Filter posts

Navigating the Rare Disease World

The international orphan drug marketplace is expected to grow some 30 percent by 2014, fueled …

Show Me the Money: Reimbursement in an ACA World

A panel at the BIO CEO & Investor Conference focused on reimbursement discussed value from a …

Orphan Drugs: Making Rare Diseases Rarer

A panel at the BIO CEO & Investor Conference provided an analysis of the thriving …

Small Biotech Companies and China: 5 Keys to Success

Big pharmaceutical countries aren’t the only ones investing in China. Emerging and mid-sized biotech companies are also …

Despite Low Funding, Biotech Productivity Remains High In 2013

At the 2013 BIO CEO & Investor Conference, John Milligan, President and COO of Gilead …

Tracks & Attendees Put the “International” in the BIO International Convention

As the BIO International Convention celebrates its 20th year, there is no time like the present …

Onyx CEO One of 25 Most Influential People in Biopharm Today According to FierceBiotech

After a stellar year, as evidenced by inclusion in the second annual FierceBiotech “25 Most …

How to Survive the Patent Cliff: Eli Lilly’s CEO at the BIO CEO & Investor Conference

Like a number of companies, Eli Lilly is confronting a wave of patent expirations called …

Word on the Street – Biotech Stocks Only Have Room to Go Up

The Opening Lunch Plenary at this year’s BIO CEO & Investor Conference was a lively …

Celgene CEO on New Multiple Myeloma Drug Approvals

Following on the heels of two big announcements in February, Celgene CEO Robert Hugin (one …